Home
Tests sections
3186. PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

All test sections

Choose the category you’re interested in

TOP tests

What to check

For whom

Check-up

Biomaterial

3186. PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

Turnaround time (days): 3

1135 ₴

Important information

*FOR WOMEN ONLY

*The service can be ordered independently or as an add-on within 14 days from the date of ordering services 4276; 4281; 4282; 4273; 4041.

*Collection of urogenital biomaterial is not available in all departments.

*Before your visit, check the presence of a corresponding mark on the page of the selected branch.

Description

Screening test for detecting 14 high-risk human papillomavirus (HPV) genotypes. Performed by real-time PCR on the Cobas® platform (FDA approved).

Provides individual genotyping for HPV 16 and 18 and pooled detection of 12 other high-risk types, in accordance with Order No. 1057 of the Ministry of Health of Ukraine (June 18, 2024).

Automated test for detecting 14 high-risk human papillomavirus (HPV) types with separate genotyping for HPV 16 and 18. The test is designed for the qualitative detection of HPV DNA in cervical cells. It is performed on the modern Cobas 6800 platform (Roche, Switzerland) using multiplex amplification and real-time fluorescent detection.

The test separately identifies HPV 16 and HPV 18 – the most oncogenic types responsible for up to 70% of cervical cancer cases. It additionally detects 12 other high-risk HPV types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. This test covers the full list of oncogenic types recommended for screening by the Ministry of Health of Ukraine (Order No. 1057), the FDA (USA), and the WHO.

This is important because HPV is the most common sexually transmitted infection (STI) worldwide: up to 90% of women are exposed to the virus during their lifetime. In most cases, the infection is transient – the immune system eliminates the virus within 1–2 years. Chronic HPV persistence (especially types 16 and 18) is associated with the development of cervical intraepithelial neoplasia (CIN I–III), cervical cancer (including adenocarcinoma), and HPV-associated cancers of other sites (vulva, vagina, anal canal, oropharynx).

DNA is extracted from cervical cell samples. Using multiplex PCR, the system determines the presence of oncogenic HPV types. In case of a positive result: HPV 16/18 – immediate further examination is recommended (colposcopy, biopsy). Other high-risk HPV types – further management is determined individually based on combined factors: Pap test results, age, medical history, and presence of dysplasia.

Advantages of this test:

full automation – minimization of human error;
high sensitivity and specificity (FDA clinical validation); early detection of HPV 16/18 – highest risk of CIN2+/CIN3+;
14 types in one report – comprehensive result;
compliance with international and Ukrainian protocols (Order of the Ministry of Health of Ukraine No. 1057).

PCR. HPV HR 14 (cobas HPV, FDA approved) – a modern, fully automated, and clinically validated method for detecting high-risk HPV, enabling timely diagnosis of precancerous changes and cervical cancer. Its use complies with international screening standards and significantly improves the quality of risk-based patient management.

When and who needs the test?

primary screening in women aged 25 and older, once every 5 years (according to MOH Order No. 1057);
women with abnormal Pap test results (ASC-US, LSIL, HSIL);
suspected HPV-associated cervical changes;
co-testing (Pap + HPV test) – the recommended modern screening approach.

Biological material

Site-specific scrapings collected depending on the test

Preparation for cytology

Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
Avoid sexual intercourse for 3 days.
Exclude douching and the use of vaginal...

Cheaper in a package

4285. Package # 250 (Cervical screening, COTESTING: Liquid-based cytology PAP test (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved) and PCR. HPV HCR 14 (cobas HPV FDA approved).

Number of tests: 2

Liquid-based cytology PAP test (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved).

PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

Turnaround time (days): 3

1610 ₴

3393. Пакет №152 (ПЛР. ВПЛ 6, 11 та ВПЛ ВКР 14 (сobas HPV схвалений FDA))

Number of tests: 2

PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

PCR. HPV 6, 11 (qualitative determination)

Turnaround time (days): 3

2060 ₴

3394. Пакет №38.1 (Урогенітальне здоров'я 2: ПЛР:Chlamydia trachomatis/Mycoplasma hominis/Mycoplasma genitalium/Ureaplasma species/Trichomonas vaginalis/Gardnerella vaginalis/Neisseria gonorrhoeae/ВПЛ6/11/ВКР14 (сobas HPV FDA) (у/г зішкріб).Бакпосів.УГ.Комплекс)

Number of tests: 10

Bacterial culture. Urogenital complex (Lactobacillus spp., Gardnerella vaginalis, Enterococcus spp., Staphylococcus spp., Streptococcus spp., Enterobacterales, Non-fermenters, Candida spp., and others). Automatic identification. Antimicrobial resistance pr

PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

Turnaround time (days): 3

8160 ₴

3186. PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)

1135 ₴